Osimertinib Poised To Be New First-line Standard EGFRm NSCLC Osimertinib Poised To Be New First-line Standard EGFRm NSCLC

Osimertinib, a third-generation EGFR inhibitor, significantly improved PFS over current standard-of-care therapies in advanced NSCLC harboring EGFR mutations.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news